07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

HI-1640V: Preliminary Phase IIb data

Preliminary data from the double-blind, Australian Phase IIb HI-H005 trial in 287 evaluable patients with moderate to severe COPD showed that oral HI-164OV did not reduce the number of exacerbations requiring corticosteroid treatment or hospitalization,...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
01:29 , Jun 29, 2012 |  BC Extra  |  Clinical News

Bioxyne reports Phase IIb COPD data for HI-164OV

Bioxyne Ltd. (ASX:BXN) reported preliminary data from the Phase IIb HI-H005 trial to treat moderate to severe chronic obstructive pulmonary disease (COPD) showing that oral HI-164OV did not reduce the number of exacerbations requiring corticosteroid...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Hunter Immunology, Probiomics deal

Probiomics completed its acquisition of Hunter Immunology after raising A$2.4 million ($2.5 million) in a public offer earlier in March. The company subsequently delisted from the Australian Securities Exchange (ASX) and implemented a 1-for-20 share...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Hunter Immunology, Probiomics deal

Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock deal values Hunter, an unlisted public company, at about A$29.7 million ($29.4 million). Details were not disclosed. Probiomics said...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Taking the ADR route

Taking the ADR route Company Exchange Symbol Country Depositary bank (A) Date Solbec OTC SLBPY Australia BNY 4/18/05 pSivida NASD PSDV Australia CIT 1/27/05 Antisense Therapeutics OTC ATHJY Australia BNY 1/10/05 Regenera OTC RGNFY Australia...